JP2020525548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525548A5 JP2020525548A5 JP2020522278A JP2020522278A JP2020525548A5 JP 2020525548 A5 JP2020525548 A5 JP 2020525548A5 JP 2020522278 A JP2020522278 A JP 2020522278A JP 2020522278 A JP2020522278 A JP 2020522278A JP 2020525548 A5 JP2020525548 A5 JP 2020525548A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- pharmaceutical composition
- composition according
- compound
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 42
- 229940125904 compound 1 Drugs 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 230000000977 initiatory effect Effects 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 230000028709 inflammatory response Effects 0.000 claims description 8
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims description 8
- 108020001588 κ-opioid receptors Proteins 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 239000002632 kappa opiate receptor agonist Substances 0.000 claims description 6
- 208000004454 Hyperalgesia Diseases 0.000 claims description 5
- 208000035154 Hyperesthesia Diseases 0.000 claims description 5
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims description 5
- 108700023159 delta Opioid Receptors Proteins 0.000 claims description 5
- 102000048124 delta Opioid Receptors Human genes 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 208000019775 Back disease Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010013954 Dysphoria Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010028836 Neck pain Diseases 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 206010038678 Respiratory depression Diseases 0.000 claims description 2
- 206010039897 Sedation Diseases 0.000 claims description 2
- 208000032140 Sleepiness Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 230000008848 allosteric regulation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 230000036280 sedation Effects 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529285P | 2017-07-06 | 2017-07-06 | |
| US62/529,285 | 2017-07-06 | ||
| PCT/US2018/038936 WO2019010014A1 (en) | 2017-07-06 | 2018-06-22 | OPIOID KAPPA AND DELTA AGONIST WITH DOUBLE ACTION LIMITED TO PERIPHERY FOR ANALGESIA IN PAIN CONDITIONS INVOLVING INFLAMMATORY RESPONSE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525548A JP2020525548A (ja) | 2020-08-27 |
| JP2020525548A5 true JP2020525548A5 (enExample) | 2021-08-05 |
| JP7233741B2 JP7233741B2 (ja) | 2023-03-07 |
Family
ID=64950308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522278A Active JP7233741B2 (ja) | 2017-07-06 | 2018-06-22 | 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11185551B2 (enExample) |
| EP (1) | EP3649132B1 (enExample) |
| JP (1) | JP7233741B2 (enExample) |
| KR (1) | KR20200026962A (enExample) |
| CN (2) | CN111278831A (enExample) |
| AU (1) | AU2018297214B2 (enExample) |
| CA (1) | CA3067398A1 (enExample) |
| IL (1) | IL271772A (enExample) |
| SG (1) | SG11201912036XA (enExample) |
| WO (1) | WO2019010014A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022260648A1 (en) * | 2021-06-07 | 2022-12-15 | Uwm Research Foundation, Inc. | Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0799051B1 (en) * | 1994-12-12 | 2005-07-27 | Omeros Corporation | Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| WO2002102232A2 (en) * | 2001-06-14 | 2002-12-27 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
| US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
| EA201691489A1 (ru) | 2014-01-24 | 2016-12-30 | Кадила Хелзкэр Лимитед | Новые гетероциклические соединения в качестве агонистов каппа-опиодиов |
-
2018
- 2018-06-22 KR KR1020207003510A patent/KR20200026962A/ko not_active Ceased
- 2018-06-22 US US16/066,184 patent/US11185551B2/en active Active
- 2018-06-22 SG SG11201912036XA patent/SG11201912036XA/en unknown
- 2018-06-22 CN CN201880057624.3A patent/CN111278831A/zh active Pending
- 2018-06-22 JP JP2020522278A patent/JP7233741B2/ja active Active
- 2018-06-22 CN CN202310638988.3A patent/CN116440140A/zh active Pending
- 2018-06-22 AU AU2018297214A patent/AU2018297214B2/en active Active
- 2018-06-22 CA CA3067398A patent/CA3067398A1/en active Pending
- 2018-06-22 EP EP18828790.8A patent/EP3649132B1/en active Active
- 2018-06-22 WO PCT/US2018/038936 patent/WO2019010014A1/en not_active Ceased
-
2019
- 2019-12-30 IL IL271772A patent/IL271772A/en unknown
-
2021
- 2021-10-25 US US17/509,158 patent/US20220288089A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9205086B2 (en) | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| JP2009541223A5 (enExample) | ||
| US20230012615A1 (en) | Methods for treatment of fibrotic diseases | |
| JP2002538176A (ja) | トラマドール物質および選択的ｃｏｘ−２阻害薬を含んで成る組成物 | |
| US20160220574A1 (en) | Nsaid and sigma receptor ligand combinations | |
| KR20180054657A (ko) | Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법 | |
| RU2019121667A (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| RU2017145976A (ru) | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна | |
| CN105120868A (zh) | 组合治疗 | |
| PH12021550554A1 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| AU2014301220A1 (en) | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) | |
| JP2021138703A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| JP2020525548A5 (enExample) | ||
| US20160220576A1 (en) | Isoxazole compound for the treatment of cancer | |
| JP5786714B2 (ja) | 神経障害性疼痛の治療剤又は予防剤 | |
| CN105497019A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| JP2007523148A (ja) | 疼痛の軽減方法 | |
| WO2023158610A1 (en) | Hdac inhibitor oki-179 in combination with binimetinib for the treatment of cancer | |
| JP2018517788A (ja) | リンパ腫を治療するためにベリノスタットおよびプララトレキサートを使用する組合せ療法 | |
| WO2020106454A3 (en) | Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction | |
| WO2024249559A3 (en) | Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction | |
| TW200512204A (en) | A method of treating breast cancer with androgen receptor antagonists | |
| MX341177B (es) | Compuestos de morfina. | |
| TN2010000600A1 (en) | Use of pyrimidylamidnobenzamide derivatives for the treatment of fibrosis |